FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA
The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
More News: Brain | Narcolepsy | Neurology | Neurosurgery | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine